Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis
August 04 2020 - 8:30AM
Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced a distribution agreement with De
Novo Software™ to provide customers with access to a data analysis
solution for the high-parameter data files generated by mass
cytometry using De Novo’s FCS Express™ 7 Flow software.
Under the distribution agreement, new purchases
of the Fluidigm® Helios™ mass cytometer and Hyperion™ Imaging
System will include a one-year license for FCS Express 7 Flow for
suspension data analysis. FCS Express enables rapid generation of
analysis reports, manual or semi-automated high-dimensional
analysis tools and custom report templates. De Novo Software has
been a leading provider of cytometry analysis tools since 1998 and
provides data analysis solutions for flow and mass cytometry and
for Imaging Mass Cytometry™.
FCS Express Flow, De Novo Software’s flagship
product, is a popular cytometry analysis solution widely used by
clinical, academic and pharmaceutical institutions. FCS Express
Flow provides the flexibility to design custom analysis templates,
with streamlined outputs into Microsoft® Office applications, while
maintaining high-resolution graphics and reports.
“There are more than 1,000 significant
publications based on mass cytometry, a technology that provides
researchers with extraordinary capabilities in interrogating the
tissue microenvironment to explore important questions in
developmental biology, disease progression and response to
therapy,” said Chris Linthwaite, Fluidigm President
and CEO. “In order to fully realize the value of these rich
datasets, novel analysis methods are essential. We are pleased to
offer our customers access to the considerable capabilities
provided by De Novo’s software solutions.”
FCS Express combines analysis capabilities,
statistical applications and high-dimensional data reduction
software in a single product.
“Fluidigm mass cytometry technology is the
perfect partner for FCS Express,” said David Novo, President of De
Novo Software. “Fluidigm continues to push the boundaries in
high-parameter cytometry data, and FCS Express has all the
high-dimensional data visualization and analysis tools required to
handle such data without the need for researchers to become
biostatisticians or software coders. We are pleased to
collaborate with Fluidigm to provide researchers with new and more
powerful insights.”
About
FluidigmFluidigm (Nasdaq:FLDM) is an industry-leading
biotechnology tools provider with a vision to improve life
through comprehensive health insight. We focus on the most pressing
needs in translational and clinical research, including cancer,
immunology, and immunotherapy. Using proprietary CyTOF® and
microfluidics technologies, we develop, manufacture, and market
multi-omic solutions to drive meaningful insights in health and
disease, identify biomarkers to inform decisions, and accelerate
the development of more effective therapies. Our customers are
leading academic, government, pharmaceutical, biotechnology, and
plant and animal research laboratories worldwide. Together with
them, we strive to increase the quality of life for all. For more
information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF,
Helios, Hyperion, and Imaging Mass Cytometry are trademarks and/or
registered trademarks of Fluidigm Corporation in the
United States and/or other countries. All other trademarks are
the sole property of their respective owners. Fluidigm products are
provided for Research Use Only. Not for use in diagnostic
procedures.
About De Novo SoftwareDe Novo
Software is a leading provider of flow and image cytometry data
analysis. Its primary product, FCS Express, is used by over 3,000
laboratories worldwide for research purposes, and many clinical
laboratories for high-throughput clinical analysis. As the first
third-party flow analysis software listed with the FDA for in-vitro
diagnostic use, and with a full suite of 21 CFR Part 11 compliance
features, FCS Express is the analysis tool of choice for the
clinical laboratory. In addition, De Novo Software has extensive
experience creating custom data analysis solutions and integrating
with large scale LIS and HIS systems. For more information, please
visit www.denovosoftware.com/partnership-fluidigm.
Forward-Looking Statements for
FluidigmThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, expected features and
benefits of products and a software distribution arrangement.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to
risks relating to the potential adverse effects of the coronavirus
pandemic on our business and operating results during 2020;
challenges inherent in developing, manufacturing, launching,
marketing, and selling new products; uncertainties in contractual
relationships; risks relating to company research and development,
sales, marketing, and distribution plans and capabilities;
reductions in research and development spending or changes in
budget priorities by customers; interruptions or delays in the
supply of components or materials for, or manufacturing of,
Fluidigm products; seasonal variations in customer operations;
potential product performance and quality issues; intellectual
property risks; and competition. Information on these and
additional risks and uncertainties and other information
affecting Fluidigm business and operating results is
contained in Fluidigm’s Annual Report on Form 10-K for the year
ended December 31, 2019, and in its other filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our
website (fluidigm.com), investor site (investors.fluidigm.com),
corporate Twitter account (@fluidigm), Facebook page
(facebook.com/Fluidigm), and LinkedIn page
(linkedin.com/company/fluidigm-corporation) as channels of
distribution of information about our products, our planned
financial and other announcements, our attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contacts: Media: Mark Spearman
Senior Director, Corporate Communications 650 243 6621
mark.spearman@fluidigm.com
Investors: Agnes Lee Vice President, Investor
Relations 650 416 7423 agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024